

2020 Drug Addiction Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

<https://marketpublishers.com/r/283292E4DA82EN.html>

Date: February 2020

Pages: 169

Price: US\$ 1,999.00 (Single User License)

ID: 283292E4DA82EN

Abstracts

The 2020 Drug Addiction pipeline report presents a comprehensive overview of the research and development of Drug Addiction drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Three drugs in Research phase, 26 drugs in Pre-clinical phase, ten drugs in Phase 1, and Eight drugs in Phase 2

As of February 2020, the Drug Addiction pipeline remains robust with 48 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Drug Addiction treatment. Diverse types of targeted therapies are being explored through clinical trials including 5-HT1A receptor agonist; 5-HT2B receptor antagonist; Adrenergic uptake inhibitors; Aldehyde dehydrogenase 2 inhibitors; Alpha 3 Beta 4 nicotinic receptor antagonists; Cannabinoid receptor agonists; Cannabinoid receptor CB1 antagonists; Corticotropin releasing hormone inhibitors; CYSLTR1 antagonist; Dopamine Receptors agonist; dopamine transporter inhibitor; Dopamine uptake inhibitors; FAAH (Fatty Acid Amide Hydrolase) inhibitor; GABA A receptor agonists; Glucocorticoid receptor antagonists; GABA B receptor modulators; gamma opioid antagonist; HDAC3 protein inhibitors; kappa-opioid receptor antagonist; metabotropic glutamate receptor 2 agonist; metabotropic glutamate receptor 3 agonist; Metabotropic glutamate receptor 4 agonists; metabotropic glutamate receptor 5 antagonist; Mu Opiate Receptors agonist; Nicotinic receptor antagonists; noradrenaline transporter inhibitor; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists; Orexin receptor 1 antagonists; oxytocin receptor agonist; PDE3 inhibitor; PDE4 inhibitor; PDE7 inhibitor; Serotonin Receptors agonist; serotonin transporter inhibitor; Serotonin uptake inhibitors; Trace Amine-Associated Receptor 1 Agonist.

The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Drug Addiction drug development history, latest news, and other developments.

It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.

PUBLISHER EXPERTISE

VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.

SCOPE:

The report scope comprises of both pre-clinical phase and clinical phase development drugs for Drug Addiction development

Drug Addiction pipeline compounds and molecules under study by both large scale and small companies are included in the report

Drug Addiction pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered

Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered

Further, orphan drug status, fast track designation, different grants awarded and special status for Drug Addiction pipeline candidates included

Business overview and snapshot of all companies involved in Drug Addiction pipeline are included

Latest market and pipeline developments are provided in the report

Drug Addiction pipeline companies included in the report are- Addex Therapeutics Ltd, Aelis Farma SAS, Amygdala Neurosciences Inc, Aphios Corp, Astellas Pharma Inc, Astraea Therapeutics LLC, BioCorRx Inc, Camino Pharma LLC, Charleston Laboratories Inc, Chiesi Farmaceutici SpA, Conseгна Pharma Inc, Curemark LLC, Daya Drug Discoveries Inc, DD Therapeutics LLC, Denovo Biopharma LLC, Embera NeuroTherapeutics Inc, EncepHeal Therapeutics Inc, Eolas Therapeutics Inc, F. Hoffmann-La Roche Ltd, Foresee Pharmaceuticals Co Ltd, IMV Inc, Intervexion Therapeutics LLC, Intra-Cellular Therapies Inc, Kdac Therapeutics Inc, KemPharm Inc, Kinaxis Therapeutics Pty Ltd, Kyorin Pharmaceutical Co Ltd, MAKScientific LLC, Mind Medicine Inc, NLS Pharma Group, Novartis AG, Omeros Corp, Orexigen Therapeutics Inc, Paion AG, Protagenic Therapeutics Inc, Saniona AB, Sen-Jam Pharmaceutical LLC, Seropeutics LLC, Sosei Heptares, SpringWorks Therapeutics LLC, Tonix Pharmaceuticals Holding Corp, Tonix Pharmaceuticals Holding Corp, Zelda Therapeutics Pty Ltd, Zyla Life Sciences, Zynerva Pharmaceuticals Inc

Drug Addiction pipeline drugs profiled in the report include- ADX-88178, AEF0117, ANS-6637, APH-0802 (dronabinol), ASP8062, AT-076, AT-1001, AT-121, BICX-102, SBP-0069330, Small Molecules for Drug Abuse, buprenorphine, naloxone, CM-1212, DDD-024, oxytocin, DB103 (pomaglumetad methionil), EMB-001 (metyrapone + oxazepam), dopamine, noradrenaline and serotonin transporter inhibitor for cocaine addiction, EORA101, RO5256390, FP-004, Vaccine for Cocaine Abuse, IXT-m200, ITI-333, KDAC-0001, KP879, KNX100 (SOC-1), ibudilast, AM4113, 18-MC, NLS-10, mavoglurant, OMS527, OREX-1038, OREX-1019, remimazolam, PT00114, NS-2359, Exulta-005, SERx-480, Orexin OX1 Antagonists for Addiction, PF 04457845, RBP8000, TNX-1300, Cannabinoid receptor agonists, oxycodone hydrochloride, ZYN002 (cannabidiol)

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. EXECUTIVE SUMMARY

- 2.1 Report Scope and Research Methodology
- 2.2 Introduction to Drug Addiction Condition
- 2.3 Drug Addiction Pipeline Snapshot, 2020
- 2.4 Companies investing in Drug Addiction pipeline therapeutics
- 2.5 Phase wise Drug Addiction Pipeline Candidates
- 2.6 Most Researched Mechanism of Action of Drug Addiction Pipeline Products
- 2.7 Route of Administration of Drug Addiction Pipeline Drugs

3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT

- 3.1 Addex Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
- 3.2 Aelis Farma SAS Overview, Contacts and ASD Pipeline Drugs
- 3.3 Amygdala Neurosciences Inc Overview, Contacts and ASD Pipeline Drugs
- 3.4 Aphios Corp Overview, Contacts and ASD Pipeline Drugs
- 3.5 Astellas Pharma Inc Overview, Contacts and ASD Pipeline Drugs
- 3.6 Astraea Therapeutics LLC Overview, Contacts and ASD Pipeline Drugs
- 3.7 BioCorRx Inc Overview, Contacts and ASD Pipeline Drugs
- 3.8 Camino Pharma LLC Overview, Contacts and ASD Pipeline Drugs
- 3.9 Charleston Laboratories Inc Overview, Contacts and ASD Pipeline Drugs
- 3.10 Chiesi Farmaceutici SpA Overview, Contacts and ASD Pipeline Drugs
- 3.11 Consegna Pharma Inc Overview, Contacts and ASD Pipeline Drugs
- 3.12 Curemark LLC Overview, Contacts and ASD Pipeline Drugs
- 3.13 Daya Drug Discoveries Inc Overview, Contacts and ASD Pipeline Drugs
- 3.14 DD Therapeutics LLC Overview, Contacts and ASD Pipeline Drugs
- 3.15 Denovo Biopharma LLC Overview, Contacts and ASD Pipeline Drugs
- 3.16 Embera NeuroTherapeutics Inc Overview, Contacts and ASD Pipeline Drugs
- 3.17 EncepHeal Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
- 3.18 Eolas Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
- 3.19 F. Hoffmann-La Roche Ltd Overview, Contacts and ASD Pipeline Drugs
- 3.20 Foresee Pharmaceuticals Co Ltd Overview, Contacts and ASD Pipeline Drugs

- 3.21 IMV Inc Overview, Contacts and ASD Pipeline Drugs
- 3.22 InterveXion Therapeutics LLC Overview, Contacts and ASD Pipeline Drugs
- 3.23 Intra-Cellular Therapies Inc Overview, Contacts and ASD Pipeline Drugs
- 3.24 Kdac Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
- 3.25 KemPharm Inc Overview, Contacts and ASD Pipeline Drugs
- 3.26 Kinosis Therapeutics Pty Ltd Overview, Contacts and ASD Pipeline Drugs
- 3.27 Kyorin Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
- 3.28 MAKScientific LLC Overview, Contacts and ASD Pipeline Drugs
- 3.29 Mind Medicine Inc Overview, Contacts and ASD Pipeline Drugs
- 3.30 NLS Pharma Group Overview, Contacts and ASD Pipeline Drugs
- 3.31 Novartis AG Overview, Contacts and ASD Pipeline Drugs
- 3.32 Omeros Corp Overview, Contacts and ASD Pipeline Drugs
- 3.33 Orexigen Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
- 3.34 Paion AG Overview, Contacts and ASD Pipeline Drugs
- 3.35 Protagenic Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
- 3.36 Saniona AB Overview, Contacts and ASD Pipeline Drugs
- 3.37 Sen-Jam Pharmaceutical LLC Overview, Contacts and ASD Pipeline Drugs
- 3.38 Seropeutics LLC Overview, Contacts and ASD Pipeline Drugs
- 3.39 Sosei Heptares Overview, Contacts and ASD Pipeline Drugs
- 3.40 SpringWorks Therapeutics LLC Overview, Contacts and ASD Pipeline Drugs
- 3.41 Tonix Pharmaceuticals Holding Corp Overview, Contacts and ASD Pipeline Drugs
- 3.42 Tonix Pharmaceuticals Holding Corp Overview, Contacts and ASD Pipeline Drugs
- 3.43 Zelda Therapeutics Pty Ltd Overview, Contacts and ASD Pipeline Drugs
- 3.44 Zyla Life Sciences Overview, Contacts and ASD Pipeline Drugs
- 3.45 Zynerba Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs

4. ACTIVE PIPELINE DRUG DETAILS, 2020

- 4.1 ADX-88178 Drug Details
 - 4.1.1 ADX-88178 Current Status
 - 4.1.2 ADX-88178 Drug Overview
 - 4.1.3 ADX-88178 Mechanism of Action
 - 4.1.4 ADX-88178 Licensing/Collaboration Companies
 - 4.1.5 ADX-88178 Clinical Trials
- 4.2 AEF0117 Drug Details
 - 4.2.1 AEF0117 Current Status
 - 4.2.2 AEF0117 Drug Overview
 - 4.2.3 AEF0117 Mechanism of Action
 - 4.2.4 AEF0117 Licensing/Collaboration Companies

- 4.2.5 AEF0117 Clinical Trials
- 4.3 ANS-6637 Drug Details
 - 4.3.1 ANS-6637 Current Status
 - 4.3.2 ANS-6637 Drug Overview
 - 4.3.3 ANS-6637 Mechanism of Action
 - 4.3.4 ANS-6637 Licensing/Collaboration Companies
 - 4.3.5 ANS-6637 Clinical Trials
- 4.4 APH-0802 (dronabinol) Drug Details
 - 4.4.1 APH-0802 (dronabinol) Current Status
 - 4.4.2 APH-0802 (dronabinol) Drug Overview
 - 4.4.3 APH-0802 (dronabinol) Mechanism of Action
 - 4.4.4 APH-0802 (dronabinol) Licensing/Collaboration Companies
 - 4.4.5 APH-0802 (dronabinol) Clinical Trials
- 4.5 ASP8062 Drug Details
 - 4.5.1 ASP8062 Current Status
 - 4.5.2 ASP8062 Drug Overview
 - 4.5.3 ASP8062 Mechanism of Action
 - 4.5.4 ASP8062 Licensing/Collaboration Companies
 - 4.5.5 ASP8062 Clinical Trials
- 4.6 AT-076 Drug Details
 - 4.6.1 AT-076 Current Status
 - 4.6.2 AT-076 Drug Overview
 - 4.6.3 AT-076 Mechanism of Action
 - 4.6.4 AT-076 Licensing/Collaboration Companies
 - 4.6.5 AT-076 Clinical Trials
- 4.7 AT-1001 Drug Details
 - 4.7.1 AT-1001 Current Status
 - 4.7.2 AT-1001 Drug Overview
 - 4.7.3 AT-1001 Mechanism of Action
 - 4.7.4 AT-1001 Licensing/Collaboration Companies
 - 4.7.5 AT-1001 Clinical Trials
- 4.8 AT-121 Drug Details
 - 4.8.1 AT-121 Current Status
 - 4.8.2 AT-121 Drug Overview
 - 4.8.3 AT-121 Mechanism of Action
 - 4.8.4 AT-121 Licensing/Collaboration Companies
 - 4.8.5 AT-121 Clinical Trials
- 4.9 BICX-102 Drug Details
 - 4.9.1 BICX-102 Current Status

- 4.9.2 BICX-102 Drug Overview
- 4.9.3 BICX-102 Mechanism of Action
- 4.9.4 BICX-102 Licensing/Collaboration Companies
- 4.9.5 BICX-102 Clinical Trials
- 4.10 SBP-0069330 Drug Details
 - 4.10.1 SBP-0069330 Current Status
 - 4.10.2 SBP-0069330 Drug Overview
 - 4.10.3 SBP-0069330 Mechanism of Action
 - 4.10.4 SBP-0069330 Licensing/Collaboration Companies
 - 4.10.5 SBP-0069330 Clinical Trials
- 4.11 Small Molecules for Drug Abuse Drug Details
 - 4.11.1 Small Molecules for Drug Abuse Current Status
 - 4.11.2 Small Molecules for Drug Abuse Drug Overview
 - 4.11.3 Small Molecules for Drug Abuse Mechanism of Action
 - 4.11.4 Small Molecules for Drug Abuse Licensing/Collaboration Companies
 - 4.11.5 Small Molecules for Drug Abuse Clinical Trials
- 4.12 buprenorphine Drug Details
 - 4.12.1 buprenorphine Current Status
 - 4.12.2 buprenorphine Drug Overview
 - 4.12.3 buprenorphine Mechanism of Action
 - 4.12.4 buprenorphine Licensing/Collaboration Companies
 - 4.12.5 buprenorphine Clinical Trials
- 4.13 naloxone Drug Details
 - 4.13.1 naloxone Current Status
 - 4.13.2 naloxone Drug Overview
 - 4.13.3 naloxone Mechanism of Action
 - 4.13.4 naloxone Licensing/Collaboration Companies
 - 4.13.5 naloxone Clinical Trials
- 4.14 CM-1212 Drug Details
 - 4.14.1 CM-1212 Current Status
 - 4.14.2 CM-1212 Drug Overview
 - 4.14.3 CM-1212 Mechanism of Action
 - 4.14.4 CM-1212 Licensing/Collaboration Companies
 - 4.14.5 CM-1212 Clinical Trials
- 4.15 DDD-024 Drug Details
 - 4.15.1 DDD-024 Current Status
 - 4.15.2 DDD-024 Drug Overview
 - 4.15.3 DDD-024 Mechanism of Action
 - 4.15.4 DDD-024 Licensing/Collaboration Companies

- 4.15.5 DDD-024 Clinical Trials
- 4.16 oxytocin Drug Details
 - 4.16.1 oxytocin Current Status
 - 4.16.2 oxytocin Drug Overview
 - 4.16.3 oxytocin Mechanism of Action
 - 4.16.4 oxytocin Licensing/Collaboration Companies
 - 4.16.5 oxytocin Clinical Trials
- 4.17 DB103 (pomaglumetad methionil) Drug Details
 - 4.17.1 DB103 (pomaglumetad methionil) Current Status
 - 4.17.2 DB103 (pomaglumetad methionil) Drug Overview
 - 4.17.3 DB103 (pomaglumetad methionil) Mechanism of Action
 - 4.17.4 DB103 (pomaglumetad methionil) Licensing/Collaboration Companies
 - 4.17.5 DB103 (pomaglumetad methionil) Clinical Trials
- 4.18 EMB-001 (metyrapone + oxazepam) Drug Details
 - 4.18.1 EMB-001 (metyrapone + oxazepam) Current Status
 - 4.18.2 EMB-001 (metyrapone + oxazepam) Drug Overview
 - 4.18.3 EMB-001 (metyrapone + oxazepam) Mechanism of Action
 - 4.18.4 EMB-001 (metyrapone + oxazepam) Licensing/Collaboration Companies
 - 4.18.5 EMB-001 (metyrapone + oxazepam) Clinical Trials
- 4.19 dopamine, noradrenaline and serotonin transporter inhibitor for cocaine addiction Drug Details
 - 4.19.1 dopamine, noradrenaline and serotonin transporter inhibitor for cocaine addiction Current Status
 - 4.19.2 dopamine, noradrenaline and serotonin transporter inhibitor for cocaine addiction Drug Overview
 - 4.19.3 dopamine, noradrenaline and serotonin transporter inhibitor for cocaine addiction Mechanism of Action
 - 4.19.4 dopamine, noradrenaline and serotonin transporter inhibitor for cocaine addiction Licensing/Collaboration Companies
 - 4.19.5 dopamine, noradrenaline and serotonin transporter inhibitor for cocaine addiction Clinical Trials
- 4.20 EORA101 Drug Details
 - 4.20.1 EORA101 Current Status
 - 4.20.2 EORA101 Drug Overview
 - 4.20.3 EORA101 Mechanism of Action
 - 4.20.4 EORA101 Licensing/Collaboration Companies
 - 4.20.5 EORA101 Clinical Trials
- 4.21 RO5256390 Drug Details
 - 4.21.1 RO5256390 Current Status

- 4.21.2 RO5256390 Drug Overview
- 4.21.3 RO5256390 Mechanism of Action
- 4.21.4 RO5256390 Licensing/Collaboration Companies
- 4.21.5 RO5256390 Clinical Trials
- 4.22 FP-004 Drug Details
 - 4.22.1 FP-004 Current Status
 - 4.22.2 FP-004 Drug Overview
 - 4.22.3 FP-004 Mechanism of Action
 - 4.22.4 FP-004 Licensing/Collaboration Companies
 - 4.22.5 FP-004 Clinical Trials
- 4.23 Vaccine for Cocaine Abuse Drug Details
 - 4.23.1 Vaccine for Cocaine Abuse Current Status
 - 4.23.2 Vaccine for Cocaine Abuse Drug Overview
 - 4.23.3 Vaccine for Cocaine Abuse Mechanism of Action
 - 4.23.4 Vaccine for Cocaine Abuse Licensing/Collaboration Companies
 - 4.23.5 Vaccine for Cocaine Abuse Clinical Trials
- 4.24 IXT-m200 Drug Details
 - 4.24.1 IXT-m200 Current Status
 - 4.24.2 IXT-m200 Drug Overview
 - 4.24.3 IXT-m200 Mechanism of Action
 - 4.24.4 IXT-m200 Licensing/Collaboration Companies
 - 4.24.5 IXT-m200 Clinical Trials
- 4.25 ITI-333 Drug Details
 - 4.25.1 ITI-333 Current Status
 - 4.25.2 ITI-333 Drug Overview
 - 4.25.3 ITI-333 Mechanism of Action
 - 4.25.4 ITI-333 Licensing/Collaboration Companies
 - 4.25.5 ITI-333 Clinical Trials
- 4.26 KDAC-0001 Drug Details
 - 4.26.1 KDAC-0001 Current Status
 - 4.26.2 KDAC-0001 Drug Overview
 - 4.26.3 KDAC-0001 Mechanism of Action
 - 4.26.4 KDAC-0001 Licensing/Collaboration Companies
 - 4.26.5 KDAC-0001 Clinical Trials
- 4.27 KP879 Drug Details
 - 4.27.1 KP879 Current Status
 - 4.27.2 KP879 Drug Overview
 - 4.27.3 KP879 Mechanism of Action
 - 4.27.4 KP879 Licensing/Collaboration Companies

- 4.27.5 KP879 Clinical Trials
- 4.28 KNX100 (SOC-1) Drug Details
 - 4.28.1 KNX100 (SOC-1) Current Status
 - 4.28.2 KNX100 (SOC-1) Drug Overview
 - 4.28.3 KNX100 (SOC-1) Mechanism of Action
 - 4.28.4 KNX100 (SOC-1) Licensing/Collaboration Companies
 - 4.28.5 KNX100 (SOC-1) Clinical Trials
- 4.29 ibudilast Drug Details
 - 4.29.1 ibudilast Current Status
 - 4.29.2 ibudilast Drug Overview
 - 4.29.3 ibudilast Mechanism of Action
 - 4.29.4 ibudilast Licensing/Collaboration Companies
 - 4.29.5 ibudilast Clinical Trials
- 4.30 AM4113 Drug Details
 - 4.30.1 AM4113 Current Status
 - 4.30.2 AM4113 Drug Overview
 - 4.30.3 AM4113 Mechanism of Action
 - 4.30.4 AM4113 Licensing/Collaboration Companies
 - 4.30.5 AM4113 Clinical Trials
- 4.31 18-MC Drug Details
 - 4.31.1 18-MC Current Status
 - 4.31.2 18-MC Drug Overview
 - 4.31.3 18-MC Mechanism of Action
 - 4.31.4 18-MC Licensing/Collaboration Companies
 - 4.31.5 18-MC Clinical Trials
- 4.32 NLS-10 Drug Details
 - 4.32.1 NLS-10 Current Status
 - 4.32.2 NLS-10 Drug Overview
 - 4.32.3 NLS-10 Mechanism of Action
 - 4.32.4 NLS-10 Licensing/Collaboration Companies
 - 4.32.5 NLS-10 Clinical Trials
- 4.33 mavoglurant Drug Details
 - 4.33.1 mavoglurant Current Status
 - 4.33.2 mavoglurant Drug Overview
 - 4.33.3 mavoglurant Mechanism of Action
 - 4.33.4 mavoglurant Licensing/Collaboration Companies
 - 4.33.5 mavoglurant Clinical Trials
- 4.34 OMS527 Drug Details
 - 4.34.1 OMS527 Current Status

- 4.34.2 OMS527 Drug Overview
- 4.34.3 OMS527 Mechanism of Action
- 4.34.4 OMS527 Licensing/Collaboration Companies
- 4.34.5 OMS527 Clinical Trials
- 4.35 OREX-1038 Drug Details
 - 4.35.1 OREX-1038 Current Status
 - 4.35.2 OREX-1038 Drug Overview
 - 4.35.3 OREX-1038 Mechanism of Action
 - 4.35.4 OREX-1038 Licensing/Collaboration Companies
 - 4.35.5 OREX-1038 Clinical Trials
- 4.36 OREX-1019 Drug Details
 - 4.36.1 OREX-1019 Current Status
 - 4.36.2 OREX-1019 Drug Overview
 - 4.36.3 OREX-1019 Mechanism of Action
 - 4.36.4 OREX-1019 Licensing/Collaboration Companies
 - 4.36.5 OREX-1019 Clinical Trials
- 4.37 remimazolam Drug Details
 - 4.37.1 remimazolam Current Status
 - 4.37.2 remimazolam Drug Overview
 - 4.37.3 remimazolam Mechanism of Action
 - 4.37.4 remimazolam Licensing/Collaboration Companies
 - 4.37.5 remimazolam Clinical Trials
- 4.38 PT00114 Drug Details
 - 4.38.1 PT00114 Current Status
 - 4.38.2 PT00114 Drug Overview
 - 4.38.3 PT00114 Mechanism of Action
 - 4.38.4 PT00114 Licensing/Collaboration Companies
 - 4.38.5 PT00114 Clinical Trials
- 4.39 NS-2359 Drug Details
 - 4.39.1 NS-2359 Current Status
 - 4.39.2 NS-2359 Drug Overview
 - 4.39.3 NS-2359 Mechanism of Action
 - 4.39.4 NS-2359 Licensing/Collaboration Companies
 - 4.39.5 NS-2359 Clinical Trials
- 4.40 Exulta-005 Drug Details
 - 4.40.1 Exulta-005 Current Status
 - 4.40.2 Exulta-005 Drug Overview
 - 4.40.3 Exulta-005 Mechanism of Action
 - 4.40.4 Exulta-005 Licensing/Collaboration Companies

- 4.40.5 Exulta-005 Clinical Trials
- 4.41 SERx-480 Drug Details
 - 4.41.1 SERx-480 Current Status
 - 4.41.2 SERx-480 Drug Overview
 - 4.41.3 SERx-480 Mechanism of Action
 - 4.41.4 SERx-480 Licensing/Collaboration Companies
 - 4.41.5 SERx-480 Clinical Trials
- 4.42 Orexin OX1 Antagonists for Addiction Drug Details
 - 4.42.1 Orexin OX1 Antagonists for Addiction Current Status
 - 4.42.2 Orexin OX1 Antagonists for Addiction Drug Overview
 - 4.42.3 Orexin OX1 Antagonists for Addiction Mechanism of Action
 - 4.42.4 Orexin OX1 Antagonists for Addiction Licensing/Collaboration Companies
 - 4.42.5 Orexin OX1 Antagonists for Addiction Clinical Trials
- 4.43 PF 04457845 Drug Details
 - 4.43.1 PF 04457845 Current Status
 - 4.43.2 PF 04457845 Drug Overview
 - 4.43.3 PF 04457845 Mechanism of Action
 - 4.43.4 PF 04457845 Licensing/Collaboration Companies
 - 4.43.5 PF 04457845 Clinical Trials
- 4.44 RBP8000 Drug Details
 - 4.44.1 RBP8000 Current Status
 - 4.44.2 RBP8000 Drug Overview
 - 4.44.3 RBP8000 Mechanism of Action
 - 4.44.4 RBP8000 Licensing/Collaboration Companies
 - 4.44.5 RBP8000 Clinical Trials
- 4.45 TNX-1300 Drug Details
 - 4.45.1 TNX-1300 Current Status
 - 4.45.2 TNX-1300 Drug Overview
 - 4.45.3 TNX-1300 Mechanism of Action
 - 4.45.4 TNX-1300 Licensing/Collaboration Companies
 - 4.45.5 TNX-1300 Clinical Trials
- 4.46 Cannabinoid receptor agonists Drug Details
 - 4.46.1 Cannabinoid receptor agonists Current Status
 - 4.46.2 Cannabinoid receptor agonists Drug Overview
 - 4.46.3 Cannabinoid receptor agonists Mechanism of Action
 - 4.46.4 Cannabinoid receptor agonists Licensing/Collaboration Companies
 - 4.46.5 Cannabinoid receptor agonists Clinical Trials
- 4.47 oxycodone hydrochloride Drug Details
 - 4.47.1 oxycodone hydrochloride Current Status

- 4.47.2 oxycodone hydrochloride Drug Overview
- 4.47.3 oxycodone hydrochloride Mechanism of Action
- 4.47.4 oxycodone hydrochloride Licensing/Collaboration Companies
- 4.47.5 oxycodone hydrochloride Clinical Trials
- 4.48 ZYN002 (cannabidiol) Drug Details
 - 4.48.1 ZYN002 (cannabidiol) Current Status
 - 4.48.2 ZYN002 (cannabidiol) Drug Overview
 - 4.48.3 ZYN002 (cannabidiol) Mechanism of Action
 - 4.48.4 ZYN002 (cannabidiol) Licensing/Collaboration Companies
 - 4.48.5 ZYN002 (cannabidiol) Clinical Trials

5. LATEST DRUG ADDICTION PIPELINE NEWS AND DEALS

6. APPENDIX

- 6.1 Our Databases and Reports
- 6.2 Research Methodolgy

I would like to order

Product name: 2020 Drug Addiction Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

Product link: <https://marketpublishers.com/r/283292E4DA82EN.html>

Price: US\$ 1,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/283292E4DA82EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

